Phase 3 Readout
URGN: Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- UroGen Pharma Ltd. (URGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
- Company
- UroGen Pharma Ltd. (URGN)
- Indication
- Bladder Cancer; Urothelial Carcinoma Bladder; Urothelial Carcinoma